Ghent, Belgium – April 27, 2012 – Trinean NV today announced the appointment of
Philippe Stas as it’s new CEO, succeeding Dr. Marc Zabeau, who remains a member of
the board of directors. Simultaneously, Trinean announced that the company has secured
2.7 million euro of growth financing provided by its existing investors.
“We are delighted to have Philippe on board to help drive the value of Trinean’s
molecular spectroscopy solutions,” commented Dr. Gaston Matthyssens, chairman of the
board and managing partner at Vesalius Biocapital. “We would like to thank Dr. Marc
Zabeau for his outstanding contribution to the company over the past 5 years, supporting
the company since it spun out from the University of Ghent, and for his continued
commitment to the company as a board member.”
Prior to joining Trinean, Philippe Stas was CEO of Algonomics NV, a Belgium based
biotech service provider, where he ensured the growth and subsequent trade sale of the
company to Lonza Group AG (SIX Swiss Ex:LONN) in 2009. Since then, he was the
director and main driver of Lonza’s Applied Protein Services division in Cambridge (UK).
Earlier, Philippe Stas held positions at Perkin Elmer and Keygene. Philippe holds a M.Sc.
in Bio-engineering (Brussels Univ.), a M.Sc. in Information Technology (Hasselt Univ.),
an MBA (Univ. of Liverpool) and AMP at the Vlerick Management School.
Philippe Stas, CEO of Trinean: “It is a pleasure to join this dynamic team, delivering a
unique molecular spectroscopy platform for automated and advanced analytics.”
Trinean raised 2.7 million euro to further accelerate the development of its premium
analytical platform, comprising highly accurate spectrophotometry instruments, state-ofthe-
art analytical software, proprietary disposables for standardized micro-volume
sample analysis and highly flexible lab-automation tools.
“The continued support of Trinean’s first-in-class investors, allows us to accelerate the
development of the company and to unveil its full potential”, Philippe further comments,
adding “Trinean will strongly expand its sales, marketing and distribution channels”.
The first closing of this financing round was led by the Trineans’ current investors
Vesalius Biocapital, Capital-E, Baekeland II Fund and Fidimec.
Trinean is a Belgium based instrumentation company, bringing micro-volume molecular
spectroscopy to the next level by combining best in class analytical software with a highly
standardized read-out platform.
Founded in 2006 as a spin-out of the University of Ghent, Belgium, the company
developed a high throughput spectrophotometer, the DropSense96™, with
unprecedented capabilities, using microfluidic chips for standardized sample analysis (the
DropPlate-S™ and DropPlate-D+™ for single and dual read-outs). The Trinean platform is
complemented with a software toolbox (including DropControl™, DropQuant™, cDrop™)
for improved data interpretation and lab-automation.
Entering the market end of 2009, the DropSense96 is currently employed globally at over
For more information about Trinean, visit www.trinean.com
April 27, 2012 2/3 For immediate release
About Vesalius Biocapital
Vesalius Biocapital Partners is a European venture capital firm that focuses on the
creation and growth of pan-European early-stage life science companies. The managed
Vesalius Biocapital funds invest in areas with a high unmet medical need and a significant
profit potential: new therapeutics, cutting-edge medical devices, innovative drug delivery
technologies and diagnostic tests and instruments with a high utility level. The expertise
of the team ranges from extensive investment and exit experience to operational
experience in general management, business development, product development, IP,
and finance of start-ups and more mature life science companies.
For more information, see www.vesaliusbiocapital.com
Capital-E is an early stage venture fund focused exclusively on micro- and nanoelectronics
as well as new materials related ventures in Europe. Through its entrenched
relationship with IMEC, the largest independent research centre in micro- and nanoelectronics
in Europe, the fund and its ventures can directly rely on the support of over
1,600 specialised scientists and engineers, as well as leverage on IMEC’s 500+ worldwide
industrial partners. The fund is managed by an independent team with a balanced mix of
entrepreneurial, industrial and VC experience.
More information can be obtained at www.capital-e.com
About Baekeland II fund
In 2005 the partners of the Ghent University Association, together with Fortis Private
Equity Belgium, KBC Private Equity, Ethias, Volksvermogen and the ARKimedes Fund,
established the Baekeland Fund II, with a capital of EUR 11.1 million. Baekeland Fund II
is building on the positive experience of the first Baekeland Fund. Baekeland Fund II
invests mainly in high-tech companies that have grown out of research labs at Ghent
University, Hogeschool Gent, Arteveldehogeschool or Hogeschool West-Vlaanderen.
Baekeland Fund II is operationally managed by the Technology Transfer Department of
Ghent University, assisted by investment managers from KBC Private Equity and Fortis
Private Equity Belgium.
For more information: www.baekelandfonds.be
FIDIMEC NV is the investment vehicle of IMEC, supporting the creation and growth of its
spin-off companies. It is FIDIMEC’s mission to enable the growth of the start-up from the
earliest phase on to become a successful company
For more information, see www.fidimec.com
ir. Philippe Stas
Chief Executive Officer
Dulle Grietlaan 17/3
B-9050 Gent – Belgium